RHHBF - Kodiak Sciences Offers Multiple Shots On Goal For Eye Treatments Multiple Catalysts Expected In 2022

• Kodiak Sciences is expected to have three trial readouts in 2022 with use of its drug KSI-301. If all studies end up being successful, then 3 BLA filings would happen.
• The first most important trial readout would be from the phase 2b/3 DAZZLE study using KSI-301 to treat patients with Wet AMD.
• It is estimated that the global Wet-AMD market will reach $10.4 billion by 2024.
• Early stage programs are promising, especially Kodiak being able to possibly develop a triplet inhibitor known as KSI-601, which will be used to treat patients with Dry AMD.
• Kodiak Sciences ended 2020 with roughly $969 million in cash, cash equivalents and marketable securities. The cash on hand should be enough until the company releases results from all 3 studies using KSI-301 in 2022.

For further details see: